SCTX (Scribe Therapeutics) Cash per Share: $3.30 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
8 GF Score
Price $30.01
! 1 Warning Sign
View Full Analysis

What is Scribe Therapeutics Cash per Share?

Scribe Therapeutics SCTX +0.70% 8 Cash per Share is $3.30 as of Dec. 2025. GuruFocus rates SCTX with a GF Score™ of 8/100. The stock has 1 warning sign investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Scribe Therapeutics's Cash per Share for the quarter that ended in Dec. 2025 was $3.30.

Scribe Therapeutics  (NAS:SCTX) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Scribe Therapeutics Cash per Share Related Terms

Scribe Therapeutics Cash per Share Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics Cash per Share Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
Cash per Share
5.98 3.30

Scribe Therapeutics Semi-Annual Data
Dec24 Dec25
Cash per Share 5.98 3.30
SCTX
8GF Score
Scribe Therapeutics Inc SCTX
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scribe Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Scribe Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=57.963/17.58
=3.30

Scribe Therapeutics's Cash per Share for the quarter that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=57.963/17.58
=3.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $3.30 mean?
Scribe Therapeutics (SCTX) has a Cash per Share of $3.30 as of Dec. 2025. Cash per share is the per-share value of a company's available cash. View historical data for Scribe Therapeutics and its competitors.
Is Scribe Therapeutics' Cash per Share too high?
Scribe Therapeutics' current Cash per Share is $3.30. Overall, Scribe Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Scribe Therapeutics' Cash per Share compare to ARTV and CABA?
Scribe Therapeutics' Cash per Share of $3.30 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Scribe Therapeutics and its competitors. Scribe Therapeutics's current Cash per Share is $3.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scribe Therapeutics stock overvalued right now?
Scribe Therapeutics (SCTX) has a current Cash per Share of $3.30. The current Cash per Share is $3.30. Scribe Therapeutics' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Scribe Therapeutics (SCTX), the current Cash per Share is $3.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scribe Therapeutics Business Description

Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score

Get the complete analysis for SCTX

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.01
Price